Navigation Links
YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
Date:6/23/2009

MISSISSAUGA, ON, June 23 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that its licensee for nimotuzumab, Daiichi-Sankyo Co., Ltd. in Japan advises that it has commenced enrollment of a Phase II trial evaluating nimotuzumab in combination with radiation therapy/cisplatin/vinorelbine in first-line curative intent patients with Stage III non-small-cell lung cancer (NSCLC). The trial will evaluate the treatment completion rate and numerous secondary endpoints including response rate, progression-free survival, and the overall survival rate at 12 and 18 months as well as toxicity.

"This is the latest of eleven Phase II and III trials currently being conducted by YM and/or its four licensees, highlighting the tremendous breadth of clinical activity focused on nimotuzumab and the benefits of our cooperative model which permits the undertaking of such a comprehensive international program," said David Allan, Chairman and CEO of YM BioSciences. "Of these trials, three involve patients with NSCLC at various stages - curative, palliative radiotherapy and metastatic. NSCLC is an important indication for nimotuzumab as treatments typically involve radiation-containing regimens that have been demonstrated to enhance the expression of EGFR. Nimotuzumab's differentiated mechanistic attributes result in it selectively targeting tissues over-expressing EGFR while avoiding normal tissue. The debilitating and dangerous side effects observed with the marketed EGFR-targeted drugs result from their indiscriminant targeting of normal healthy tissues in addition to their binding to tumor."

YM and its licensee Kuhnil Pharmaceutical Co. in Korea recently collaborated
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 This webinar ... nonclinical and clinical safety assessment in biosimilars. , Regulatory ... for biosimilar drug development, however the complex nature of ... quality, safety and efficacy extremely challenging. Based on the ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... today by CSL Behring at the 2012 ... that a balanced, human 4-factor prothrombin complex concentrate (PCC) ... in stopping bleeding in patients receiving vitamin K antagonist ... frozen plasma is the standard treatment for warfarin reversal. ...
... A new bio-inspired approach to synthesising polymers will offer unprecedented ... nanomedicine, researchers say. In a study published last week ... the University of New South Wales in Sydney and the ... method of polymer synthesis based on a combination of segregation ...
... a team including scientists from the National Institute of Standards ... different properties depending on the method by which they are ... explore the best way of creating these films, which are ... devices. Thin films spread atop a surface have many ...
Cached Biology Technology:CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care 2CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care 3CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care 4Bio-inspired polymer synthesis enhances structure control 2Fabrication method can affect the use of block copolymer thin films 2
(Date:4/23/2014)... HUNTSVILLE, TX (4/23/14) -- Researchers have found evidence ... risk factors that increase aggressive behavior in children, ... that not all children exposed to prenatal smoking ... others will not," said Brian Boutwell, Assistant Professor ... Justice and senior author on the study. ...
(Date:4/23/2014)... as an antimicrobial ingredient in soaps, toothpastes and other ... new evidence that appears to support these worries. Their ... in Toxicology , found that triclosan, as well as ... human breast cancer cells in lab dishes and breast ... note that hormonal imbalances seem to play a role ...
(Date:4/23/2014)... to date of the family of bacteria that ... strategies and reveals surprising findings about the bacteria,s ... public health strategies to control this respiratory disease, ... Genomic analysis of 343 strains of the ... collected over the last 100 years illustrates how ...
Breaking Biology News(10 mins):Genetics risk, prenatal smoking may predict behavioral problems 2In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Impact of whooping cough vaccination revealed 2
... The University of Utah is launching a six-year, $21.5 ... materials for uses ranging from faster computers and communications devices ... Center of Excellence in Materials Research and Innovation is being ... grant from the National Science Foundation (NSF), $6.5 million for ...
... reversible adhesives; tenaciously clinging barnacles; and surfaces that rub ... topics that will be presented at the AVS 58th ... place Oct. 30 - Nov. 4, 2011, at the ... press registration to journalists; see details below. Journalists may ...
... Three leading sci-tech experts described engineering trends for ... this summer at the Directors Guild in Los ... of Sciences (NAS) Science & Entertainment Exchange to ... and scientists that engage the public in television, ...
Cached Biology News:$21.5 million for materials research at the University of Utah 2$21.5 million for materials research at the University of Utah 3Media invited: AVS 58th International Symposium and Exhibition 2Media invited: AVS 58th International Symposium and Exhibition 3Media invited: AVS 58th International Symposium and Exhibition 4Media invited: AVS 58th International Symposium and Exhibition 5IEEE-USA/NAS Hollywood Forum describes engineering trends for entertainment industry professionals 2
... filter (S37100, Photographic Filters for Fluorescent ... for black-and-white photography of gels stained ... stain, the safer ethidium bromide alternative. ... filter is identical to the SYPRO ...
Enodgenous alkaline phosphotase inhibitor. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM....
Several Pichia pastoris strains are available to allow you to optimize expression and recovery of your protein of interest. Table 1 provides information to help you choose the appropriate strain....
Standard 2" or 3" Plastic can be ordered with 81 or 100 cell dividers. Mini 2" Plastics Boxes come standard with 25 cell dividers. Plastic boxes can also be ordered with corresponding freezer racks...
Biology Products: